MRI contrast developer Pharmacyclics of Sunnyvale, CA, has signed a contract manufacturing agreementwith Burroughs Wellcome for production of the company's Gadoliteagent. Pharmacyclics is developing Gadolite for enhancement ofMRI scans of the abdomen and
MRI contrast developer Pharmacyclics of Sunnyvale, CA, has signed a contract manufacturing agreementwith Burroughs Wellcome for production of the company's Gadoliteagent. Pharmacyclics is developing Gadolite for enhancement ofMRI scans of the abdomen and pelvis. The agent last month completedphase-three clinical trials and Pharmacyclics plans to submita new drug application in the middle of this year.
Study: AI Boosts Ultrasound AUC for Predicting Thyroid Malignancy Risk by 34 Percent Over TI-RADS
February 17th 2025In a study involving assessment of over 1,000 thyroid nodules, researchers found the machine learning model led to substantial increases in sensitivity and specificity for estimating the risk of thyroid malignancy over traditional TI-RADS and guidelines from the American Thyroid Association.
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.